Olinvacimab (TTAC-0001) is a human monoclonal antibody targeting VEGFR-2/KDR with anti-angiogenic activity that blocks tumor angiogenesis and may be used to study solid tumors.

VEGF C to VEGFR2:6.3 nM, VEGF D to VEGFR2:7.0 nM, VEGF:0.23 nM (Kd)

Olinvacimab binds VEGF and blocks its binding to the receptor KDR with a Kd value of 0.23 nM.[1]
Olinvacimab inhibits the binding of VEGF-165, VEGF-C, and VEGF-D to VEGFR-2 with IC50 values of 8.7 nM, 6.3 nM, and 7.0 nM, respectively.[1]
Olinvacimab (0.5-30 μg/mL; 30 min) reduced the phosphorylation levels of VEGFR-2/KDR and ERK.[1] Olinvacimab was shown to reduce VEGFR-2/KDR and ERK phosphorylation levels. [1]
Olinvacimab (1, 15, 20 mg/mL; 30 min) blocks VEGF-stimulated proliferation of human umbilical vein endothelial cells. [1]
Olinvacimab (20 mg/mL; 30 min) Reduces VEGF-induced migration of human umbilical vein endothelial cells. [1]
Olinvacimab (5, 10, 20 μg; 20 hours) demonstrated dose-dependent inhibition of angiogenesis and disruption of tubular structure. [1]

Olinvacimab (100 ng; subcutaneous injection, single dose) Inhibits angiogenesis in vivo. [1]

Human

Monoclonal

Unconjugated